Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
8,875
Total Claims
$1.3M
Drug Cost
697
Beneficiaries
$1,872
Cost/Patient
Risk Score Breakdown 41/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+715%
Opioid rate vs peers
18.3% vs 2.2% avg
+33%
Cost per patient vs peers
$1,872 vs $1,411 avg
+8%
Brand preference vs peers
11.5% vs 10.6% avg
⚠️ This provider has metrics more than 3 standard deviations above their specialty average in one or more categories.
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
Opioid prescribing rate is 715% above the average for Internal Medicine providers. While some providers legitimately treat pain-heavy populations, deviations of this magnitude are rare and warrant examination.
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
18.3%
Opioid Rate
1,620
Opioid Claims
$42K
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 1,014 claims · $1.1M
Generic: 7,809 claims · $215K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Bictegrav/Emtricit/Tenofov Ala | 24 | $97K |
| Valbenazine Tosylate | 11 | $94K |
| Semaglutide | 49 | $56K |
| Fluticasone/Umeclidin/Vilanter | 43 | $49K |
| Apixaban | 48 | $49K |
| Empagliflozin | 35 | $45K |
| Sitagliptin Phosphate | 37 | $42K |
| Hydrocodone/Acetaminophen | 1,458 | $39K |
| Linaclotide | 44 | $34K |
| Rivaroxaban | 26 | $30K |
| Linagliptin | 17 | $27K |
| Umeclidinium Brm/Vilanterol Tr | 37 | $22K |
| Liraglutide | 18 | $21K |
| Dulaglutide | 16 | $19K |
| Tirzepatide | 11 | $15K |
Prescribing Profile
Patient Profile
69
Avg Age
56%
Female
1.96
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About